tbuckley/cabot-search huggingface dataset:
Association of Special Supplemental Nutrition Program for Women, Infants, and Children With Preterm Birth and Infant Mortality
Authors: Samir Soneji, Hiram Beltrán-Sánchez
Journal: JAMA Network Open (2019)

<h3>Importance</h3> Nearly 4 in 10 expectant mothers in the United States received Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) benefits during pregnancy between 2011 and 2017. Despite public support for the program, empirical evidence of the success of the program varies substantially. <h3>Objective</h3> To assess the association of WIC program participation during pregnancy by low-income expectant mothers covered by Medicaid with infant mortality by gestational age at birth and by maternal race/ethnicity in comparison with their counterparts who did not receive WIC benefits. <h3>Design, Setting, and Participants</h3> This cohort study obtained data from January 1, 2011, to December 31, 2017, from US live birth certificates. Data were from 11 148 261 expectant mothers who delivered live births in states that have implemented the 2003 revision of the US live birth certificate and whose insurance coverage and receipt of WIC benefits were recorded on the birth certificates. Data analysis was performed from June 2019 to October 2019. <h3>Exposures</h3> Receipt of WIC benefits during pregnancy. <h3>Main Outcomes and Measures</h3> The first outcome was gestational age at birth: extremely preterm (&lt;28 weeks), very preterm (28-32 weeks), moderate-to-late preterm (32-37 weeks), and normal term (≥37 weeks) births. The second outcome was death within the first year of life. <h3>Results</h3> Among the 11 148 261 expectant mothers who delivered live births between 2011 and 2017 and were covered by Medicaid during pregnancy, the modal age at delivery was 20 to 24 years, the predominant race/ethnicity was non-Hispanic white (4 257 790 [38.2%]), and 8 145 770 (73.1%) received WIC benefits during pregnancy. The proportion of expectant mothers covered by Medicaid who also received WIC benefits decreased from 2011 to 2017 (79.3% to 67.9%;<i>P</i> &lt; .001). The odds of preterm birth compared with normal term birth were lower among expectant mothers covered by Medicaid who received WIC benefits during pregnancy compared with their counterparts who did not receive WIC benefits during pregnancy (adjusted proportional odds ratio, 0.87; 95% CI, 0.86-0.87). The odds of mortality within 1 year of birth were lower for infants whose mothers were covered by Medicaid and received WIC benefits during pregnancy compared with those who did not receive WIC benefits during pregnancy (adjusted odds ratio, 0.84; 95% CI, 0.83-0.86). <h3>Conclusions and Relevance</h3> This study found that receipt of WIC benefits among expectant mothers with Medicaid coverage was associated with lower risk of preterm birth and infant mortality.
A Multicenter Experience with Single Agent Bortezomib in Non-Hodgkin’s Lymphoma Reveals Marked Differences in Sub-Type Sensitivity to Proteasome Inhibition.
Authors: Owen O’Connor, John Wright, Craig Moskowitz, Barbara MacGregor-Cortelli, David Straus, Andrew Evans, Jane Winter, Omer Koc, Nancy Horvath, Susan Blumel, Julie Vose, David Schenkein, Andrew Zelenetz
Journal: Blood (2004)
Gene Alterations and Expression of Hematopoietic Transcription Factors in Pediatric Acute Megakaryoblastic Leukemia (AMKL): A Comparison of Down Syndrome (DS)-Associated AMKL with Non-DS-AMKL.
Authors: Asahito Hama, Hiroshi Yagasaki, Hideki Muramatsu, Nobuhiro Nishio, Akihiro Abe, Yoshiyuki Takahashi, Seiji Kojima
Journal: Blood (2008)
Targeting the STING pathway in tumor-associated macrophages regulates innate immune sensing of gastric cancer cells
Authors: Lei Miao, Jingjing Qi, Qi Zhao, Qi-Nian Wu, Da-Liang Wei, Xiao-Li Wei, Jia Liu, Jun Chen, Zhao-Lei Zeng, Huai-Qiang Ju, Hui-yan Luo, Rui-Hua Xu
Journal: Theranostics (2019)

Rationale: STING is a critical player in the innate and adaptive immune system, sensing cytosolic DNA to activate the expression of interferon genes and regulate T lymphocytes, which drives immunogenic responses to cancer cells. Tumor-associated macrophages (TAMs), abundantly present in the tumor microenvironment, play a key role in cancer development. Gastric cancer is one of the most common and leading causes in cancer-related death worldwide. However, studies on the function and regulation of STING in TAMs and their roles in gastric cancer progression are still limited. Methods: We analyzed STING and CD68 expression of 200 pairs of gastric cancer and adjacent normal tissues by immunohistochemistry to identify the prognostic values of STING, as well as the correlations between STING and CD68 in gastric cancer. The characteristics of STING-altered macrophages, as well as their effects on cancer cell apoptosis and T cell differentiation were examined by flow cytometry. Cytokines secreted by STING-altered macrophages were identified by the Human Inflammation Array3 kit. Concentrations of soluble IL24 and IFN-β were measured by ELISA. In vivo models, including spontaneous gastric cancer in p53+/- mice and cell line-based xenografts, were established, and clinical benefits of STING-altered macrophages were examined. Results: Our study identifies STING as a prognostic factor for gastric cancer, and for the first time demonstrated that knocking-down STING and STING activation by 2'3'-c-GAMP both promote TAMs polarizing into pro-inflammatory subtype and induce apoptosis of gastric cancer cells, mechanistically through IL6R-JAK-IL24 pathway. Conclusions : This study evaluated effects of targeting STING in TAMs in anti-gastric-cancer therapies. Moreover, we unveil a novel function of STING to activate the IL6R-JAK-IL24 pathway in macrophages.
Supramolecular nanomaterials based on hollow mesoporous drug carriers and macrocycle-capped CuS nanogates for synergistic chemo-photothermal therapy
Authors: Jie Yang, Dihua Dai, Xinyue Lou, Lianjun Ma, Bailiang Wang, Ying-Wei Yang
Journal: Theranostics (2019)

Multifunctional supramolecular nanoplatforms that integrate the advantages of different therapeutic techniques can trigger multimodal synergistic treatment of tumors, thus representing an emerging powerful tool for cancer therapeutics. Methods: In this work, we design and fabricate a multifunctional supramolecular drug delivery platform, namely Fa-mPEG@CP5-CuS@HMSN-Py nanoparticles (FaPCH NPs), consisting of a pyridinium (Py)-modified hollow mesoporous silica nanoparticles-based drug reservoir (HMSN-Py) with high loading capacity, a layer of NIR-operable carboxylatopillar[5]arene (CP5)-functionalized CuS nanoparticles (CP5-CuS) on the surface of HMSN-Py connected through supramolecular host-guest interactions between CP5 rings and Py stalks, and another layer of folic acid (Fa)-conjugated polyethylene glycol (Fa-PEG) antennas by electrostatic interactions capable of active targeting at tumor lesions, in a controlled, highly integrated fashion for synergistic chemo-photothermal therapy. Results: Fa-mPEG antennas endowed the enhanced active targeting effect toward cancer cells, and CP5-CuS served as not only a quadruple-stimuli responsive nanogate for controllable drug release but also a special agent for NIR-guided photothermal therapy. Meanwhile, anticancer drug doxorubicin (DOX) could be released from the HMSN-Py reservoirs under tumor microenvironments for chemotherapy, thus realizing multimodal synergistic therapeutics. Such a supramolecular drug delivery platform showed effective synergistic chemo-photothermal therapy both in vitro and in vivo. Conclusion: This novel supramolecular nanoplatform possesses great potential in controlled drug delivery and tumor cellular internalization for synergistic chemo-photothermal therapy, providing a promising approach for multimodal synergistic cancer treatment.
Infections caused by extended-spectrum β-lactamase-producing Enterobacterales after rectal colonization with ESBL-producing Escherichia coli or Klebsiella pneumoniae
Authors: L.A. Denkel, F. Maechler, F. Schwab, A. Kola, A. Weber, P. Gastmeier, F. Pfäfflin, S. Weber, G. Werner, Y. Pfeifer, M. Pietsch, R. Leistner
Journal: Clinical Microbiology and Infection (2019)
Characterizing Relative and Disease-Specific Survival in Early-Stage Cancers
Authors: Andrea R. Marcadis, Jennifer L. Marti, Behfar Ehdaie, A. Ari Hakimi, Louise Davies, Luc G. T. Morris
Journal: JAMA Internal Medicine (2019)

observed effect sizes are small.If researchers have a good reason to suspect systematic error in risk factor assessment, a sensitivity analysis should be conducted to assess the implications of this error on observed associations between risk factors and outcomes.
Outcome after Frontline Therapy with the Modified Hyper-CVAD Regimen with or without Rituximab for De Novo Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL).
Authors: Deborah A. Thomas, Hagop Kantarjian, Stefan Faderl, William G. Wierda, Alessandra Ferrajoli, Jan A. Burger, Jorge Cortes, Charles A. Koller, Gautam Borthakur, Zeev Estrov, Marina Konopleva, Farhad Ravandi, Guillermo Garcia- Manero, Susan O’Brien
Journal: Blood (2008)
Abstract P335: Health Care Discrimination and C-Reactive Protein in US Adults
Authors: Thu T Nguyen, M. Maria Glymour, Amani Nuru-Jeter
Journal: Circulation (2017)

Background: Healthcare discrimination has been documented and remains common in the US. However, little is known about the association between healthcare discrimination and objective health indicators such as C-reactive protein (CRP), a marker of inflammation and a correlate of cardiovascular outcomes. Methods: We used 2008-2012 data from the Health and Retirement Study, a nationally representative study of US adults ages 54+, to examine the association between self-reported experiences of healthcare discrimination and high sensitivity CRP among those reporting a history of chronic disease (N=12,110). Dried blood spots were assayed for CRP. Respondents were asked how often they received poorer service or treatment than other people from doctors or hospitals (six-point likert scale ranging from “almost every day” to “never.”) Participants reporting any healthcare discrimination were compared to those reporting “never.” We used Generalized Estimate Equation (GEE) models to examine the associations between healthcare discrimination and CRP (&lt; vs. ≥ 3 g/L), specifying a compound symmetry working correlation structure to take account of the dependency of repeated measures of the biomarker. To examine whether the relationship differs across the outcome distribution, quantile regression models were fitted, examining the 10 th , 25 th , 50 th , 75 th , and 90 th percentiles of the CRP distribution, and accounting for repeated measurements. All models were adjusted for age, sex, race/ethnicity, education, log-household size adjusted wealth and income, current employment, marital status, and year indicators. Results: In 2008, 18% of participants reported past experiences of health care discrimination. Report of healthcare discrimination was associated with increased odds of CRP ≥ 3 g/L (OR: 1.12, 95% CI: 1.02, 1.24), similar in magnitude to a 6-year age difference. Health care discrimination was not associated with CRP at the 10 th (β=0.01; 95% CI: -0.04, 0.06) or 25 th percentile (β=0.05; 95% CI: -0.03, 0.14). At the 50 th percentile (~2.1 g/L) and at 75 th percentile of CRP (~4.5 g/L), participants who reported experiencing health care discrimination had 0.14 g/L (95% CI: 0.01, 0.26) and 0.32 g/L (95% CI: -0.04, 0.61) higher CRP, respectively, than participants who did not report health care discrimination. Conclusion: Adults reporting prior healthcare discrimination have elevated levels of CRP. The estimated effect was largest for people at the higher end of the CRP distribution, who would be at greater risk of adverse cardiovascular outcomes.
포스터 발표 : 폐내 단락이 간이식의 결과에 미치는 영향
Authors: 김현영, 최문석, 이준혁, 고광철, 백승운, 유병철, 이종철
Journal: Clinical and Molecular Hepatology (2003)

배경/목적: 간폐증후군은 만성 간질환이 있는 환자에서 폐내 가스 교환의 장애로 저산소증이 유발되는 상태이다. 간이식이 간폐증후군의 유일한 치료법으로 알려져 있으나 일부 보고에 의하면 간폐증후군이 간이식의 위험인자로 작용한다고 한다. 이에 연자 등은 간폐증후군이 간이식의 결과에 미치는 영향을 알아보고자 하였다. 대상과 방법: 1999년 11월부터 2002년 11월까지 만성 간질환으로 간이식을 시행한 환자 78명을 대상으로 하였다. 조영 증강 심초음파에서 2 등급 이상의 의미 있는 폐내단락이 있는 36예(46.2%)와 폐내 단락이 없는 42예(53.8%)로 나누었고, 양 군간의 기관삽입 기간, 중환자실 재원기간, 폐합병증, 총입원 기간과 3개월 생존율을 비교하였다. 결과: 1) 폐내 단락과 간이식 후 기관삽입 기간(폐내 단락이 있는 군에서 3.2±4.9일, 폐내 단락이 없는 군에서 5.5±18.6일)과의 양군 간에 유의한 차이가 없었다.(p＞0.05) 2) 폐내단락과 간이식 후 중환자실 재원 기간(폐내 단락이 있는 군에서 12.0±8.8일, 폐내 단락이 없는 군에서 15.7±23.2일)과의 양군 간에 유의한 차이가 없었다.(p＞0.05) 3) 폐내 단락과 간이식 후 총입원 기간(폐내 단락이 있는 군에서 40.0±25.0일, 폐내 단락이 없는 군에서 39.8±24.9일)과의 양군 간에 유의한 차이가 없었다.(p＞0.05) 4) 폐내 단락과 간이식 후 폐합병증 발생률은 폐내 단락이 있는 군에서 3.8%, 폐내 단락이 없는 군에서 5.1%로 양군 간에 유의한 차이가 없었다(p＞0.05). 4) 폐내 단락의 유무와 간이식 후 3개월 단기 생존율은 폐내 단락이 있는 군에서 85.7%, 폐내 단락이 없는 군에서 86.7%로 양군 간에 유의한 차이가 없었다(p＞0.05). 결론: 이상의 결과로 폐내 단락의 유무가 간이식의 위험인자로 작용하지 않음을 알 수 있었다.
High Loading of Hydrophobic and Hydrophilic Agents via Small Immunostimulatory Carrier for Enhanced Tumor Penetration and Combinational Therapy
Authors: Jingjing Sun, Yichao Chen, Jieni Xu, Xiangping Song, Zhuoya Wan, Yuqian Du, Weina Ma, Xizhen Li, Lin Zhang, Song Li
Journal: Theranostics (2019)

Development of small-sized nanoformulations for effective tumor penetration, particularly for those tumors with dense stroma is a major challenge in cancer nanomedicine.It is even more challenging to achieve effective co-loading of both hydrophobic and hydrophilic anticancer agents through a small-sized nanocarrier.In this work, we designed a novel redox-responsive gemcitabine (GEM)-conjugated polymer POEG-co-PVDGEM (PGEM) as a small-sized nanocarrier to co-deliver hydrophilic GEM and hydrophobic paclitaxel (PTX).Methods: The in vitro physicochemical and biological properties of PTX/PGEM NPs were characterized.The efficiency of the PGEM carrier in selective codelivery of GEM and PTX in two murine tumor models as well as a patient derived xenograft model (PDX) was also evaluated.In addition, we investigated the changes in tumor immune microenvironment after treatment with PTX/PGEM nanoparticles.Results: We discovered that GEM conjugation could significantly decrease the nanoparticle size from 160 nm to 13 nm.Moreover, different from most reported GEM-conjugated polymers, PGEM polymer could serve as a prodrug carrier to load a wide variety of hydrophobic agents with high drug loading capacity and excellent stability.More importantly, our strategy could be extended to various nucleotides-based drugs such as azacytidine, decitabine and cytarabine, suggesting a new platform for co-delivery of various first line hydrophilic and hydrophobic anticancer agents.Imaging showed that our small-sized carrier was much more effective in tumor accumulation and penetration compared to the relatively large-sized drug carrier.The PGEM prodrug-based carrier not only well retained the pharmacological activity of GEM, but also boosted T-cell immune response.Furthermore, delivery of PTX via PGEM led to significantly improved antitumor activity in several murine cancer models and a PDX model of colon cancer.Conclusion: This work not only provided a small-sized carrier platform that was able to load multiple hydrophilic and hydrophobic drugs with high loading capacity, but also provided an effective regimen for enhanced tumor penetration and improved anti-tumor immunity.
Current mysteries of pachyonychia congenita
Authors: Rudolf E. Leube, Nicole Schwarz
Journal: British Journal of Dermatology (2019)

Linked Article: Zieman and Coulombe. Br J Dermatol 2020; 182:564–573. Epidermal keratinopathies are autosomal-dominant genetic skin diseases of keratin-encoding genes, which are expressed in a site- and context-dependent manner. The generally accepted function of cytoplasmic keratin filaments as major cellular stabilizers and the observed weakening of the keratin cytoskeleton by overexpression of mutant keratins gave rise to the notion that compromised mechanics are at the heart of keratinopathy (recent review in Jacob et al.1). But keratinopathies are surprisingly heterogeneous diseases presenting multiple facets ranging from epidermal fragility to epidermal hyperproliferation, topologically diverse manifestations in certain regions and epidermal appendages, and neurological symptoms including itch and debilitating pain. Only the existence of hitherto still unknown keratin isotype-specific functions can account for the observed phenotypic diversity. The focus on specific keratins is therefore a necessity to understand disease pathogenesis and to design symptomatic and targeted treatment strategies. The recent flare-up of research on the rare skin disease pachyonychia congenita (PC) affecting keratins 6, 16 and 17 addresses this need. The comprehensive review by Zieman and Coulombe2 in this issue of the BJD competently summarizes current knowledge on PC pathogenesis with particular emphasis on murine model systems. The authors distinguish three stages of PC pathogenesis leading to palmoplantar keratoderma (PPK), which is the most prominent symptom in patients with PC and also in murine PC models. The first ‘pre-PPK stage’ is characterized by a loss of palmoplantar keratin 9 with only minimal histological alterations. The subsequent ‘onset stage’ is defined by oxidative stress, which induces an Nrf2-dependent antioxidant response. It is followed by the final ‘active stage’, when normal tissue homeostasis is lost, leading to the pathognomonic PPK. This proposed pathogenic framework provides a useful concept to pursue fundamental questions, which need to be addressed, such as (see also Fig. 1): The well-characterized murine models together with patient-derived induced pluripotent stem cells8 and complex multicomponent cellular coculture systems9 provide promising leads to unravel the current mysteries of PC pathogenesis in relation to other keratinopathies for improving the treatment of affected individuals. Conflicts of interest: none to declare.
Use of Buprenorphine/Naloxone in Ameliorating Acute Care Utilization and Chronic Opioid Use in Adults with Sickle Cell Disease
Authors: Ifeyinwa (ify) Osunkwo, Padmaja Veeramreddy, Justin Arnall, Rachel Crawford, James T Symanowski, Rasaq Olaosebikan, Srinivasa Reddy Sanikommu, Stephanie Newby, Stephen Wyatt, Jamie Sebaaly, Katherine Rector
Journal: Blood (2019)
Trends in the Cost of Cancer Care: Beyond Drugs
Authors: Aaron A. Laviana, Amy N. Luckenbaugh, Matthew J. Resnick
Journal: Journal of Clinical Oncology (2019)

Article Tools REVIEW ARTICLES Health Services and Outcomes Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.19.01963 Journal of Clinical Oncology - published online before print December 5, 2019 PMID: 31804864 Trends in the Cost of Cancer Care: Beyond Drugs Aaron A. Laviana, MD1xAaron A. LavianaSearch for articles by this author; Amy N. Luckenbaugh, MD1xAmy N. LuckenbaughSearch for articles by this author; and Matthew J. Resnick, MD, MPH, MMHC1xMatthew J. ResnickSearch for articles by this author Show More 1Vanderbilt University Medical Center, Nashville, TNA.A.L. and A.N.L. contributed equally to this work. https://doi.org/10.1200/JCO.19.01963 First Page Full Text PDF Figures and Tables © 2019 by American Society of Clinical Oncology
Abstract 18163: Cardiovascular Impact of Cocaine in Regular Asymptomatic Users Assessed By Cardiovascular Magnetic Resonance Imaging
Authors: Rebecca Kozor, Stuart Grieve, Ravinay Bhindi, Gemma Figtree
Journal: Circulation (2012)

We hypothesised that significant cocaine-related cardiovascular abnormalities would be present in regular social cocaine users who are otherwise healthy, and detectable using cardiovascular magneti...
Familial Haploidentical Stem Cell Transplant in Children and Adolescents With High-Risk Sickle Cell Disease
Authors: Mitchell S. Cairo, Julie-An Talano, Theodore B. Moore, Qiuhu Shi, Rona Singer Weinberg, Brenda Grossman, Shalini Shenoy
Journal: JAMA Pediatrics (2019)

This phase 2 clinical trial in patients with high-risk sickle cell disease assesses the feasibility, safety, and 1-year event-free survival after myeloimmunoablative conditioning and familial haploidentical stem cell transplant.
Development of Adamantane-Conjugated TLR7/8 Agonists for Supramolecular Delivery and Cancer Immunotherapy
Authors: Christopher B. Rodell, Maaz S. Ahmed, Christopher S. Garris, Mikael J. Pittet, Ralph Weissleder
Journal: Theranostics (2019)

Tumor-associated macrophages (TAMs) are often abundant in solid cancers, assuming an immunosuppressive (M2-like) phenotype which supports tumor growth and immune escape. Recent methods have focused on identification of means (e.g., drugs, nanomaterials) that polarize TAMs to a tumor suppressive (M1-like) phenotype; however, reducing the systemic side effects of these therapies and enabling their delivery to TAMs has remained a challenge. Methods: Here, we develop R848-Ad, an adamantane-modified derivative of the toll-like receptor (TLR) 7/8 agonist resiquimod (R848) through iterative drug screening against reporter cell lines. The adamantane undergoes guest-host interaction with cyclodextrin nanoparticles (CDNPs), enabling drug loading under aqueous conditions and TAM-targeted drug delivery. Therapeutic efficacy and systemic side effects were examined in a murine MC38 cancer model. Results: R848-Ad retained macrophage polarizing activity through agonization of TLR7/8, and the adamantane moiety improved drug affinity for the CDNP. In preclinical studies, nanoformulated R848-Ad resulted in a drastic reduction in measurable systemic effects (loss of body weight) relative to similarly formulated R848 alone while arresting tumor growth. Conclusions: The findings demonstrate the ability of strong nanoparticle-drug interactions to limit systemic toxicity of TLR agonists while simultaneously maintaining therapeutic efficacy.
High Response Rates in Acute Steroid Refractory Graft-Versus-Host Disease (GVHD) Following Combined Tumor Necrosis Factor-alpha (TNF-α) and Interleukin-2 (IL-2) Blockade.
Authors: Ramaprasad Srinivasan, Nancy Geller, Colleen Dorrance, Igor Espinoza-Delgado, A. John Barrett, Yoshiyuki Takahashi, Richard W. Childs
Journal: Blood (2005)
Osteoclasts Are Involved in Stem Cell Mobilization: Cleavage of SDF-1 by Cathepsin K.
Authors: Orit Kollet, Robert Samstein, Asaf Spiegel, Shoham Shivtiel, Noa Hoffmann, Alexander Kalinkovich, Polina Goichberg, Tsvee Lapidot
Journal: Blood (2004)
A Novel Clinical Syndrome Associating Severe Congenital Neutropenia and Complex Developmental Aberrations Caused by Deficiency of G6PC3
Authors: Kaan Boztug, Giridharan Appaswamy, Angel Ashikov, Alejandro A Schäffer, Ulrich Salzer, Jana Diestelhorst, Manuela Germeshausen, Gudrun Brandes, Jacqueline Lee-Gossler, Fatih Noyan, Anna-Katherina Gatzke, Milen Minkov, Johann Greil, Christian Kratz, Theoni Petropoulou, Isabelle Pellier, Christine Bellanne-Chantelot, Nima Rezaei, Kirsten Mönkemöller, Noha Irani-Hakimeh, Hans Bakker, Rita Gerardy-Schahn, Cornelia Zeidler, Bodo Grimbacher, Karl Welte, Christoph Klein
Journal: Blood (2008)
Readmission-Free Period and In-Hospital Mortality at the Time of First Readmission in Acute Heart Failure Patients
Authors: Ahmed M Altibi, George Prousi Md, Mahek Shah Md, Manyoo Agarwal Md, Pradhum Ram, Byomesh K Tripathi Md, Shantanu Patil Md, Brijesh Patel Md
Journal: Circulation (2019)
Coronary flow reserve changes induced by a1– and a2- adrenergic blockade
Authors: L. Gregorini, J. Marco, Carlo Palombo, M. Kozàkovà, I. M. Bossi, I. Marco, M. Bernies, B. Cassagneau, G. B. Anguissola, S. M. Romano, F. Donatelli, J. Fajadet
Journal: Circulation (1999)